Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses overall survival results from the phase III KEYNOTE-564 study of adjuvant pembrolizumab vs placebo in patients with clear cell renal cell carcinoma (Abstract LBA359).
Andrea B. Apolo, MD, of the National Cancer Institute, National Institutes of Health, discusses the results of the AMBASSADOR Alliance A031501 study, which showed adjuvant pembrolizumab improved disease-free survival vs observation for patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. According to Dr. Apolo, the findings support adjuvant pembrolizumab as a new treatment option for this population (Abstract LBA531).
Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and limited therapeutic options. According to Dr. Grande, the existence of long-lasting responders makes it worthwhile to continue investigating predictive factors that may help to select patients for this combination therapy (Abstract 1).
Amanda Nizam, MD, of the Cleveland Clinic, discusses results from the UNITE study, which shows patients with advanced urothelial cancer who were treated with enfortumab vedotin-ejfv (EV) after switch maintenance avelumab had outcomes consistent with data with EV in platinum- and immune checkpoint inhibitor–refractory disease (Abstract 537).
Umang Swami, MD, of Huntsman Cancer Institute at the University of Utah, describes the molecular and immunologic mechanisms of metastatic tropism in advanced prostate cancer, data that may facilitate future drug development. In patients with metastatic disease, specific sites are associated with differential overall survival, but the biological reasons have not been fully explored (Abstract 21).
David H. Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses reportedly the first data to describe an inverse correlation between HER2 immunohistochemistry expression and PD-L1 combined positive score. According to Dr. Aggen, these and other findings by his team may provide a foundation for further HER2-directed advanced bladder cancer studies (Abstract 538).
